CA3246851A1 - SOLID CANCER TREATMENT BIOMARKER BY IMIDAZO[4,5-B]PYRIDINE DERIVATIVE - Google Patents

SOLID CANCER TREATMENT BIOMARKER BY IMIDAZO[4,5-B]PYRIDINE DERIVATIVE

Info

Publication number
CA3246851A1
CA3246851A1 CA3246851A CA3246851A CA3246851A1 CA 3246851 A1 CA3246851 A1 CA 3246851A1 CA 3246851 A CA3246851 A CA 3246851A CA 3246851 A CA3246851 A CA 3246851A CA 3246851 A1 CA3246851 A1 CA 3246851A1
Authority
CA
Canada
Prior art keywords
cancer
gene
myc
mutation
myc gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246851A
Other languages
English (en)
French (fr)
Inventor
Hirokazu TOZAKI
Daisuke Morishita
Akio Mizutani
Yoshihiko SATOH
Koki HIKAMI
Hiroyuki Mano
Shinji Kohsaka
Akinobu Hamada
Shigehiro YAGISHITA
Kenichi Iwai
Masahiro Yaguchi
Kazuho KUMAZAWA
Toshiyuki Nomura
Original Assignee
National Cancer Center Japan
Chordia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, Chordia Therapeutics Inc filed Critical National Cancer Center Japan
Publication of CA3246851A1 publication Critical patent/CA3246851A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3246851A 2022-03-31 2023-03-30 SOLID CANCER TREATMENT BIOMARKER BY IMIDAZO[4,5-B]PYRIDINE DERIVATIVE Pending CA3246851A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-060240 2022-03-31
JP2022060240 2022-03-31
PCT/JP2023/013361 WO2023190967A1 (ja) 2022-03-31 2023-03-30 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Publications (1)

Publication Number Publication Date
CA3246851A1 true CA3246851A1 (en) 2025-02-03

Family

ID=88202235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246851A Pending CA3246851A1 (en) 2022-03-31 2023-03-30 SOLID CANCER TREATMENT BIOMARKER BY IMIDAZO[4,5-B]PYRIDINE DERIVATIVE

Country Status (7)

Country Link
US (1) US20260108526A1 (https=)
EP (1) EP4501328A4 (https=)
JP (1) JPWO2023190967A1 (https=)
KR (1) KR20240169002A (https=)
CN (1) CN119053329A (https=)
CA (1) CA3246851A1 (https=)
WO (1) WO2023190967A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025150571A1 (ja) * 2024-01-12 2025-07-17 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 Ｃｌｋ阻害剤を有効成分として含むがん治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.
US11946934B2 (en) * 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
US10577382B2 (en) 2016-04-28 2020-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP7224645B2 (ja) 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法

Also Published As

Publication number Publication date
EP4501328A1 (en) 2025-02-05
WO2023190967A1 (ja) 2023-10-05
JPWO2023190967A1 (https=) 2023-10-05
KR20240169002A (ko) 2024-12-02
CN119053329A (zh) 2024-11-29
US20260108526A1 (en) 2026-04-23
EP4501328A4 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
US20240392378A1 (en) Methods of treating cancer
US20240011098A1 (en) Diagnostic and therapeutic methods for cancer
US20250146077A1 (en) Novel estrogen receptor mutations and uses thereof
AU2020203244B2 (en) Novel KIF5B-RET fusion molecules and uses thereof
Chae et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
EP2914622B1 (en) Novel fusion molecules and uses thereof
Romano et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression
US20150073036A1 (en) Novel ntrk1 fusion molecules and uses thereof
US20160010068A1 (en) Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
JP2022095670A (ja) 癌治療に対する感受性を予測するためのバイオマーカー
Toss et al. Cancer predisposition genes in adolescents and young adults (AYAs): a review paper from the Italian AYA working group
CN105143463A (zh) 新的雄激素受体突变
US20260108526A1 (en) BIOMARKER FOR TREATMENT OF SOLID CANCER WITH IMIDAZO[4,5-b]PYRIDINE DERIVATIVE
WO2006073202A9 (ja) GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法
JP7747459B2 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
HK40112492A (zh) 利用咪唑并[4，5-b]吡啶衍生物治疗实体瘤的生物标志物
HK40016865A (en) Kif5b-ret fusion molecules and uses thereof
Ramnarayanan et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Khuong-Quang et al. 10. School of Women's and Children's Health, UNSW Medicine, UNSW Sydney, Randwick, 2031, Australia Corresponding author: Associate Professor Paul G. Ekert, Group Leader, Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia Email: PEkert@ ccia. org. au

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240925

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241008

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250612